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Abstract
Introduction: The prevalence of arthropathy in moderate haemophilia A (MHA) and 
B (MHB) is not well known.
Aim: We evaluated joint health in Nordic patients in relation to their treatment 
modality.
Methods: A cross-sectional, multicentre study covering MHA and MHB in Sweden, 
Finland and Norway. Arthropathy was evaluated by ultrasound (HEAD-US) and 
Haemophilia Joint Health Score (HJHS).
Results: We report on 145 patients: median age 28 years (IQR 13-52) and 61% MHA. 
Baseline factor VIII/factor IX activity (FVIII/FIX:C) was 2 IU/dL (median) (IQR 2-4): 
lower for MHB (2 IU/dL, IQR 1-2) than MHA (3 IU/dL, IQR 2-4) (P < .01). Eighty-five 
per cent of MHA and 73% MHB had a history of haemarthrosis (P = .07). Age at first 
joint bleed was lower for MHA (5 years [median], IQR 3-7) than MHB (7 years, IQR 
5-12) (P = .01). Thirty-eight per cent received prophylaxis, started at median 10 years 
of age (IQR 4-24). Median joint bleeds and serious other bleeds during the last 
12 months were both zero (IQR 0-1). Total HEAD-US captured 0/48 points (median) 
(IQR 0-2) and HJHS 4/120 points (IQR 1-10) with strong correlation between them 
(r = .72). FVIII/FIX:C ≤ 3 IU/dL was associated with higher HJHS (P = .04). Fifteen per 
cent had undergone orthopaedic surgery.
Conclusion: The current joint health in Nordic moderate haemophilia patients was 
rather good, but a subgroup had severe arthropathy. FVIII/FIX:C ≤ 3 IU/dL and MHA 
were associated with a more severe bleeding phenotype. We suggest primary proph-
ylaxis to all patients with FVIII/FIX:C ≤ 3 IU/dL.
K E Y W O R D S
arthropathy, joint score, moderate haemophilia A, moderate haemophilia B, prophylaxis, 
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1  | INTRODUC TION
Arthropathy is the main long-term complication for patients with 
haemophilia. Prophylactic replacement therapy has significantly re-
duced the prevalence in severe haemophilia,1-3 and regular prophy-
laxis is now the standard of care. This has not been implemented 
in moderate haemophilia, and previous publications have suggested 
that these patients are undertreated. In a systematic review, Di 
Minno et al4 reported that 15%-77% of patients with moderate hae-
mophilia had arthropathy. Based on observations in a Dutch study, 
den Uijl et al5 proposed that patients with moderate haemophilia and 
residual factor level <3 IU/dL should receive prophylaxis after their 
first joint bleed, if this occurred within 5 years of age. More recently, 
the THUNDER study reported high bleeding rates among patients 
with moderate haemophilia A in the UK.6 Haemophilia A and B have 
usually been considered as indistinguishable diagnoses, but there 
are data suggesting that patients with severe haemophilia B have a 
less severe bleeding phenotype.7,8 Data comparing the clinical phe-
notypes in moderate haemophilia A (MHA) and B (MHB), however, 
are scarce with no clear difference between them.8,9
The Nordic countries have long traditions of prophylaxis in hae-
mophilia, pioneered by Sweden.1 Our study aimed to evaluate the 
joint health in Nordic patients with MHA and MHB in relation to 
their treatment modality.
2  | MATERIAL S AND METHODS
The MoHem study is a cross-sectional, multicentre study that 
covers MHA and MHB (factor VIII/factor IX activity [FVIII/FIX:C] 
1-5 IU/dL)10 of all ages from Sweden, Finland and Norway. There 
were no exclusion criteria. The study received approval by na-
tional ethical committees in all three countries and was performed 
in accordance with the Helsinki Declaration.11 All participants 
signed informed consents, parents on behalf of the children. 
The Nordic haemophilia care is organized through Haemophilia 
Comprehensive Care Centres (HCCC) approved by the European 
Association for Haemophilia and Allied Disorders. The enrolment 
took place at the HCCCs in Oslo, Malmö, Gothenburg, Stockholm 
and Helsinki between January 2017 and October 2019. In Sweden 
and Norway, these centres manage all patients with haemophilia. 
In Finland, there are four Haemophilia Treatment Centres across 
the country, while approximately 60% of the patients are man-
aged at the HCCC in Helsinki. Study participants were recruited 
consecutively as part of their regular follow-up and from national 
registries.
Data on treatment and medical history were self-reported and 
obtained from clinical records. Definitions of “joint bleed” and 
“on-demand” vs “prophylactic” treatment were according to rec-
ommendations from the Scientific and Standardization Committee 
(SCC) of the International Society on Thrombosis and Haemostasis 
(ISTH),10 and bleeds were recorded if they had required clotting fac-
tor replacement therapy. The ISTH-SSC bleeding assessment tool 
(ISTH-BAT)12 was used to register the patients’ lifelong cumulative 
bleeding history.
Arthropathy in index joints (elbows, knees and ankles) was eval-
uated by Haemophilia Early Arthropathy Detection with Ultrasound 
(HEAD-US)13 and Haemophilia Joint Health Score (HJHS)14 2.1 for pa-
tients above 5 years of age. HEAD-US contains a score of 0-8 points for 
each examined joint. HJHS 2.1 contains 0-20 points per joint, reaching 
a total score of 120 points, gait score excluded. In order to compare 
results assessed by HEAD-US and HJHS, we used both scores as cumu-
lative adding the points from all six examined joints. Joints that had un-
dergone arthroplasties or arthrodesis were excluded on HEAD-US, and 
these patients are therefore missing from the total score. HJHS was 
scored in a regular way in all joints. Physicians or physiotherapists who 
had attended HEAD-US preceptorship courses performed ultrasound, 
and physiotherapists affiliated to the HCCCs performed HJHS. For 
most patients, HEAD-US and HJHS were done at enrolment. For prac-
tical reasons, examinations performed within 1 year were accepted. 
Either one or two persons, according to access of qualified performers 
at the HCCC, performed HEAD-US and HJHS.
The results were analysed together as a Nordic study group 
and subdivided in four groups according to age (<15, 15-34, 35-54 
and ≥55 years). Patients on prophylaxis were compared with those 
treated on-demand, and MHA was compared with MHB. The results 
were also compared across residual FVIII/FIX:C based on histori-
cal values analysed locally at each study centre. For patients with 
several measurements, the lowest available value was used for clas-
sification. These baseline FVIII/FIX:C had been analysed both by 
one-stage and chromogenic assays.
2.1 | Statistical analyses
Statistical analyses used were mainly descriptive. Most parameters 
had a skewed distribution. Continuous data are summarized as medi-
ans and interquartile ranges (IQR), and categorical data are presented 
as numbers and percentages. We used Mann-Whitney U test and 
Spearman's correlation for comparison between continuous variables 
with skewed distribution. Student's t test was used for normally dis-
tributed data. For comparison between categorical data, we used chi-
square test. A P-value < .05 was considered statistically significant. 
Statistical analyses were performed using SPSS Statistics 26.
3  | RESULTS
We enrolled 145 patients with MHA (n = 89) and MHB (n = 56), 
representing 63% of the population of patients with moderate hae-
mophilia attending the five HCCCs. Median age was 28 years (IQR 
13-52) and 89 (61%) had MHA (Table 1). The patients not attending 
the study were older (41 years, IQR 27-56) (P < .01), but the preva-
lence of MHA (48 [57%]) was similar to the study group (P = .53). 
Non-enrolment was mainly due to practical reasons, such as long 
journey to the HCCC.
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Overall, the baseline FVIII/FIX:C was 2 IU/dL (median) (IQR 2-4) 
(Figure 1, Table 1). However, MHB had lower levels than MHA (P < .01) 
(Table 2). One hundred and four patients (72%) had FVIII/FIX:C ≤ 3 IU/
dL, 55 (53%) of these had MHA. Age at diagnosis was 2 years (median) 
(IQR 0-5) and lower for patients with a family history of haemophilia 
than others (1 year, IQR 0-4 vs 2 years, IQR 1-7) (P < .01).
3.1 | Treatment and bleeding history
Fifty-five patients (38%) were receiving prophylactic replace-
ment therapy (Table 1). Age at start of prophylaxis was 10 years 
(median) (IQR 4-24) and correlated strongly with age at enrolment 
(r = .87, P < .001) (Figure 2). Nine patients (16%) initiated prophylaxis 
<3 years of age, seven of whom were in the youngest age group 
(<15 years). The use of prophylaxis was equally distributed between 
MHA and MHB, and not related to baseline FVIII/FIX:C (Table 2). 
The median prophylactic dose was 55 IU/kg/wk (IQR 42-82) 
(Table 1). The annual factor consumption was higher among patients 
on prophylaxis (2924 IU/kg/y [median], IQR 2094-4203) compared 
with those treated on-demand (27 IU/kg/y, IQR 0-130) (P < .001). 
Overall, the annual factor consumption was equal between MHA 
and MHB (Table 2). However, among those with FVIII/FIX:C ≤ 3 IU/
dL, the consumption was lower for MHB (83 IU/kg/y [median], IQR 
0-2055) than MHA (653 IU/kg/y, IQR 99-3524) (P = .02). The an-
nual prophylactic consumption was equal between MHA and MHB. 
During the last 12 months, 34 patients (25%) did not use any replace-
ment therapy. This was irrespective of diagnosis (P = .32) and FVIII/
FIX:C (P = .78). Furthermore, during the same period, 64 patients 
(44%) used tranexamic acid and four patients (5% among MHA) used 
desmopressin.
One hundred and seventeen patients (81%) had a history of 
haemarthrosis (Table 1): 76 (85%) with MHA and 41 (73%) with MHB 
(P = .07) (Table 2). For patients with FVIII/FIX:C ≤ 3 IU/dL, this differ-
ence between MHA and MHB was statistically significant (51 [93%] 
vs 37 [76%]) (P = .02). Median age at first joint bleed was 5 years (IQR 
3-8) for the whole study group (Table 1). However, patients with 
MHA (P = .01) and those with FVIII/FIX:C ≤ 3 IU/dL (P = .03) expe-
rienced their first joint bleed at a younger age (Table 2). Overall, age 
at first joint bleed did not depend on mode of treatment (P = .16). 
Among the youngest patients (<15 years), however, prophylaxis was 
associated with a younger age at first joint bleed (3 years (median), 
IQR 1-4 vs 5 years, IQR 4-7) (P < .01).
Bleeding frequency was low: median number of joint bleeds and 
serious other bleeds during the last 12 months were both zero (IQR 
0-1). There were more joint bleeds among MHA than MHB (P = .02) 
(Table 2). The number of joint bleeds did not depend on mode of 
treatment (P = .57). Ninety-nine patients (68%) had zero joint bleeds 
during the last 12 months: more commonly among MHB (44 [79%]) 
than MHA (55 [62%]) (P = .04). ISTH-BAT score was 14 points (me-
dian) (IQR 8-19) for the whole study group. There were no differ-
ences between type of haemophilia, treatment modality or baseline 
FVIII/FIX:C.
3.2 | Arthropathy
One hundred and eighteen patients were evaluated by HEAD-US, 
and 135 were evaluated by HJHS. Total HEAD-US (n = 109) cap-
tured 0 points (median) (IQR 0-2) and total HJHS 4 points (IQR 1-10). 
Patients with FVIII/FIX:C ≤ 3 IU/dL had higher HJHS than those 
with levels > 3 IU/dL (P = .04) (Table 2). This was not observed 
with HEAD-US. Both HEAD-US and HJHS were equal between 
MHA and MHB and irrespective of mode of treatment. Sixty-one 
patients (56%) had zero points on HEAD-US, and 76 (70%) had 0-1 
TA B L E  1   Patient characteristics for the MoHem study
All patients 
(N = 145)
Age at enrolment (y) 28 (13-52)
Haemophilia A 89 (61%)
Baseline FVIII or FIX activity (IU/dL) 2 (2-4)
Family history of haemophilia 102 (70%)
Age at diagnosis (y) 2 (0-5)
History of haemarthrosis 117 (81%)
Age at first joint bleeda (y) 5 (3-8)
Currently on prophylaxis 55 (38%)
Age at start of prophylaxis (y) 10 (4-24)
FVIII/FIX prophylactic dose (IU/kg/wk) 55 (42-82)
History of inhibitor 3 (2%)
HCV-positive (Ab+/PCR+) 8 (6%)
HIV-positive 2 (1%)
Note: Numbers (%) or medians (interquartile range).
Abbreviations: FVIII, factor VIII; FIX, factor IX; HCV, hepatitis C virus; 
HIV, human immunodeficiency virus.
The number of patients (n) is noted if it deviates from the total number: 
an = 111/117.
F I G U R E  1   Baseline factor activity levels in the MoHem study 
(N = 145). The proportions of patients with moderate haemophilia 
A (MHA) and B (MHB) according to baseline factor activity (1-5 IU/
dL) are presented as separate curves
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point. Sixty-seven patients (50%) had HJHS 0-3 points, and 101 
(75%) had <10/120 points. Correlation between mean joint scores 
assessed by HEAD-US and HJHS was strong (r = .72, P < .001) 
(Figure 3), and 52 patients (79%) among those with 0-3 points on 
HJHS had zero points on HEAD-US. Both HEAD-US and HJHS 
increased by age (HEAD-US: r = .69, P < .001 and HJHS: r = .72, 
P < .001). When divided in age groups, HJHS was higher among 
patients on prophylaxis compared with those treated on-demand 
(Figure 4). Such comparison was difficult to capture in HEAD-US 
due to low numbers.
Twenty-two patients (15%) had undergone orthopaedic sur-
gery due to arthropathy, equally distributed between MHA and 
MHB, baseline FVIII/FIX:C (Table 2), and mode of treatment. Sub-
classification according to age was difficult due to low numbers. 
However, orthopaedic surgery was more frequent in the prophy-
laxis group (75% [6/8] vs 17% [3/18]) (P < .01) in the age group 
35-54 years. Ten patients had undergone surgery in more than one 
joint. Knee arthroplasties were most frequent and accounted for 18 
TA B L E  2   Outcome in moderate haemophilia A (MHA) vs B (MHB) and according to baseline factor VIII/factor IX activity (≤3 vs >3 IU/dL)
MHA (n = 89)
MHB 
(n = 56) P-value
≤3 IU/dL 
(n = 104)
>3 IU/dL 
(n = 41)
P-
value
Age at enrolment (y) 27 (12-51) 28 (15-57) .48 27 (13-50) 30 (13-59) .40
Baseline factor activity (IU/dL) 3 (2-4) 2 (1-2) <.01 - - -
Haemophilia A - - - 55 (53%) 34 (83%) <.01
History of haemarthrosis 76 (85%) 41 (73%) .07 88 (85%) 29 (71%) .06
Age at first joint bleeda (y) 5 (3-7) 7 (5-12) .01 5 (3-7) 7 (4-10) .03
Currently on prophylaxis 34 (38%) 21 (38%) .93 43 (41%) 12 (29%) .18
Age at start of prophylaxis (y) 10 (4-22) 10 (6-37) .65 9 (4-23) 17 (9-47) .11
Annual factor consumptionb (IU/kg/y) 333 (18-2600) 88 (0-2109) .14 344 (15-2670) 82 (0-2179) .78
Joint bleeds during the last 12 mo 0 (0-1) 0 (0-0) .02 0 (0-1) 0 (0-0) .09
Other bleeds during the last 12 mo 0 (0-1) 0 (0-0) .81 0 (0-1) 0 (0-1) .90
ISTH-BAT 14 (8-20) 13 (8-18) .32 13 (8-19) 14 (8-18) .98
HEAD-US totalc (0-48 points) 0 (0-2) 0 (0-2) .58 0 (0-2) 0 (0-2) .88
HJHS totald (0-120 points) 2 (0-10) 4 (1-9) .30 4 (1-10) 1 (0-9) .04
Orthopaedic surgery 16 (18%) 6 (11%) .37 16 (15%) 6 (15%) .93
Note: Numbers (%) or medians (interquartile range).
Abbreviations: HEAD-US, Haemophilia Early Arthropathy Detection with Ultrasound; HJHS, Haemophilia Joint Health Score; ISTH-BAT, 
International Society on Thrombosis and Haemostasis bleeding assessment tool.
The number of patients (n) is noted if it deviates from the total number: an = 72/76 (MHA), 39/41 (MHB), 84/88 (≤3 IU/dL) and 27/29 (>3 IU/dL); 
bn = 83/89 (MHA), 55/56 (MHB), 100/104 (≤3 IU/dL) and 38/41 (>3 IU/dL); cn = 66/89 (MHA), 43/56 (MHB), 76/104 (≤3 IU/dL) and 33/41 (>3 IU/dL); 
dn = 82/89 (MHA), 53/56 (MHB), 98/104 (≤3 IU/dL) and 37/41 (>3 IU/dL).
F I G U R E  2   Scatter plot demonstrating Spearman's correlation (r) 
between age at start of prophylaxis and age at enrolment (n = 55)
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F I G U R E  3   Scatter plot demonstrating Spearman's correlation 
(r) between mean joint scores assessed by Haemophilia Early 
Arthropathy Detection with Ultrasound (HEAD-US) and 
Haemophilia Joint Health Score (HJHS) (n = 118)
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joints in 14 patients, followed by ankle arthrodesis in 12 joints in 11 
patients.
4  | DISCUSSION
The MoHem study addresses joint health and treatment modalities 
in Nordic patients with MHA and MHB. We found an overall low 
score for HEAD-US and HJHS, and 38% were currently on prophy-
laxis. Baseline FVIII/FIX:C ≤ 3 IU/dL and MHA were associated with 
a more severe bleeding phenotype.
Through a Nordic collaboration, we have collected data on al-
most twofold as many patients as the Dutch study by den Uijl et al.5 
Our participants were slightly younger (median 28 vs 37 years of 
age) and baseline FVIII/FIX:C was a bit lower (median 2 vs 3 IU/
dL). Median age at first joint bleed was 5 years in both studies. We 
report a higher prevalence of prophylaxis (38%) than among the 
Dutch patients (23%). In both studies, however, there was a gap of 
several years between age at first joint bleed and start of prophy-
laxis. In severe haemophilia, age at start of prophylaxis has been 
found as an independent predictor for development of arthrop-
athy.15 The annual prophylactic factor consumption was three 
times higher among the Nordic patients (median 2924 vs 939 IU/
kg/y). This is in accordance with the different treatment traditions 
between the Dutch intermediate-dose and the Nordic high-dose 
regimens.16 Patients treated on-demand had four times higher fac-
tor consumption in the Dutch study (median 112 vs 27 IU/kg/y). 
Bleeding frequency was low in both studies with a median of 
zero annual joint bleeds. In the Dutch study, 82% achieved HJHS 
<10/128 points, considered as a good joint function. We report 
75% with a corresponding HJHS. A lower baseline FVIII/FIX:C 
may accord with this difference. We also included all available 
patients, even if they had a history of inhibitor (three patients), 
and regardless of the access to haemophilia care during childhood. 
Geographically, there are long distances within the Nordic coun-
tries. Combined with centralized haemophilia care, this may have 
contributed to a limited follow-up for some patients, especially 
among the elderly. The prevalence of orthopaedic surgery was 
equal in both studies.
Compared with the THUNDER study from the UK,6 we re-
port a lower prevalence of prophylaxis than among their sub-
group with MHA (38% vs 69%). Still, their bleeding frequency was 
high with median two (prophylaxis) and five annual joint bleeds 
(on-demand). In our study, the annual number was zero in both 
treatment groups. Their low baseline FVIII:C (median 1 IU/dL) may 
explain this difference. In accordance with their results, we found 
a progressive increase in HJHS and HEAD-US with age. This sug-
gests progression of haemophilic arthropathy due to inadequate 
treatment regimens in past decades and emphasizes the need of 
early start of prophylaxis.15 When divided in age groups, our study 
showed a higher HJHS among patients on prophylaxis compared 
with those treated on-demand, reflecting a more severe pheno-
type in the prophylaxis group. The gap between age at first joint 
bleed (median 5 years) and age at start of prophylaxis (median 
10 years) may further explain the deterioration of joint health 
among patients on prophylaxis.
It may also be of interest to compare our results with a former 
Swedish cohort of severe haemophilia on full-time prophylaxis.16 
Our patients with moderate haemophilia achieved HJHS ≥ 10 points 
approximately twice as often (25% vs 11%). Orthopaedic surgery 
was also more frequent among our patients (15% vs 8%). Although 
we had a slightly higher age in our study (median 28 vs 23 years), 
the most important difference is the widespread use and early age 
at start of prophylaxis in the severe haemophilia cohort. This indi-
cates an unmet need in the treatment of patients with moderate 
haemophilia.
4.1 | MHA and MHB
The MoHem study contains a high proportion of patients with MHB 
(39%), and we may therefore compare outcomes between MHA and 
MHB. Prophylaxis started at 10 years (median) in both groups. Thus, 
we may observe a more natural course of the bleeding phenotypes 
than in the PedNet/RODIN cohorts of children by Clausen et al,9 
who started prophylaxis <3 years of age. In both studies, the preva-
lence of prophylaxis was equal between MHA and MHB. However, 
we detected differences regarding history of haemarthrosis and age 
at first joint bleed pointing towards a milder phenotype in MHB. This 
was even more pronounced among those with FVIII/FIX:C ≤ 3 IU/dL, 
which represented most (88%) of our patients with MHB. Besides, 
in this subgroup, the total factor consumption during the last 
12 months was lower for MHB than for MHA. The number of joint 
bleeds was also lower among MHB. Schulman et al,8 who studied a 
Swedish adult cohort of haemophilia A and B in all severities, found 
F I G U R E  4   Box plot of Haemophilia Joint Health Score (HJHS) 
according to treatment method and age groups (n = 135). The lines 
represent median values, the boxes are interquartile ranges (IQR), 
and the whiskers are the lowest or highest observations still within 
1.5 IQR of the lower or higher quartiles. Outliers are plotted as 
individual points. HJHS was higher among patients on prophylaxis 
vs on-demand
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a difference in total severity score and annual factor consumption 
between severe haemophilia A and B, but not among moderate pa-
tients. We did not find any difference between MHA and MHB with 
respect to arthropathy.
4.2 | Baseline factor activity level
Our study showed a more severe clinical phenotype among pa-
tients with FVIII/FIX:C ≤ 3 IU/dL with respect to younger age at 
first joint bleed and higher HJHS. This is in accordance with den 
Uijl et al,17 who found a sharp bend in the haemophilia ‘early mile-
stone’ curves towards a more severe clinical phenotype below 
FVIII:C of 3 IU/dL. However, in the study on moderate haemo-
philia,5 they reported similar bleeding rates and HJHS across 
factor activity levels as opposed to our study, which might be ex-
plained by our larger cohort.
4.3 | HEAD-US and HJHS
We found a strong correlation between HEAD-US and HJHS. This 
is in accordance with previous publications18,19 and support that 
both these tools are valuable for joint assessment. However, as 
HJHS contains both structural and functional items, HEAD-US 
only assesses the joint structure. Thus, there would naturally be 
some discrepancy between them. Half of our patients had 0-3 
points on HJHS. Dependant on the HJHS items involved, and if 
the total score represents findings in a single or more joints, these 
low scores do not necessarily represent intraarticular pathology.20 
In our study, most of these patients (79%) captured zero points 
at HEAD-US, which support classifying them as within ‘normal 
range’.
4.4 | Strengths and limitations
The MoHem study reports clinical outcome in a high number of 
patients with MHA and MHB. Arthropathy was broadly evaluated 
using both HEAD-US and HJHS. Due to a centralized follow-up, we 
have reached a high degree of participation among Nordic patients 
with moderate haemophilia. The study participants represented a 
younger age group than those not enrolled; thus, our results do not 
assess the elderly patients. The centralized care provides uniform 
treatment and follow-up. Even though there were different treat-
ment traditions in previous times,21 the Nordic countries today 
follow common Nordic treatment guidelines in accordance with 
international recommendations. The multicentre design may give 
rise to inter-individual and inter-centre variability, even if we have 
struggled to provide uniform instructions to all persons involved. 
There might be misclassification of baseline FVIII/FIX:C, because 
these analyses have been performed at several laboratories at 
different time points and with different methods. However, we 
standardized the classification by using the lowest available value 
for all participants. Our data on bleeding history were collected 
retrospectively. Especially among the elderly, the documentation 
in medical records could be sparse. Although we used validated 
scores to classify haemophilic arthropathy,13,14 there might be 
some variability when several performers are involved.22 However, 
HEAD-US reliability has previously been classified as good.23,24
5  | CONCLUSION
The current joint health among Nordic moderate haemophilia patients 
was rather good, but a subgroup had severe arthropathy. Baseline 
FVIII/FIX:C ≤ 3 IU/dL was associated with a younger age at first joint 
bleed and higher HJHS. One third experienced joint bleeds during 
the last 12 months. Differences in bleeding history between MHA 
and MHB pointed towards a milder phenotype in MHB. Orthopaedic 
surgery, however, was equally performed in both diagnoses and ir-
respective of FVIII/FIX:C. Altogether, the MoHem study indicates a 
need for a more extended use of prophylaxis among patients with 
moderate haemophilia from early ages, prior to the onset of joint dis-
ease. We suggest primary prophylaxis to all patients with baseline 
FVIII/FIX:C ≤ 3 IU/dL according to similar guidelines as those for se-
vere haemophilia.
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